Clinical Trial

IP-cure-B clinical trial

Do you know that there is a clinical trial going on in the framework of the IP-cure-B project?

TheANRS HB07 clinical trial issponsored by ANRS | Emerging Infectious Diseasesand takes place in different centres across Europe involved in the project.

The objective of the EU-funded IP-cure-B project is to develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune responses with a novel therapeutic vaccine. Researchers will also identify immune and viral biomarkers for monitoring patient stratification and treatment response. Integrating biological and clinical data will enable models for the best combination of treatment and effectiveness of novel curative therapies concerning disease spectrum and patient heterogeneity. The preclinical platform will be evaluated in humanised mice, combining immune-modulatory strategies to stimulate innate immunity, rescue exhausted HBV-specific T cells and generate anti-HBV adaptive responses. Proof of concept will be obtained in a clinical trial of a combination of novel compounds stimulating innate immunity.

Outcomes for medical experts

The project aims at proposing a treatment paradigm shift with the development of novel combination therapies for CHB with improved cure rates and a better appraisal of novel biomarkers to improve patient selection for treatment and monitoring treatment response.

Outcomes for community

The development of such curative therapies with a finite duration of administration will pave the way towards a universal treatment of all individuals that suffer from chronic HBV infection. It is thus expected to result in a long-term reduction in cost and global burden of CHB (short-term therapy, increased treatment uptake in the infected population, decreased rate of liver complications and mortality).

Outcomes for patient

The project aims at designing and developing novel treatment strategies towards the cure of infection with a shorter duration of treatment. It is expected to result in improved quality of life and decreased social stigma.

 LIST OF CLINICAL TRIAL SITES
HOSPITAL HEAD OF DEPARTMENT PRINCIPAL INVESTIGATOR ADDRESS
Hospices Civils de Lyon (France) Pr. Fabien ZOULIM
[email protected]
Pr. Fabien ZOULIM
[email protected]
Telephone (secretary) : 04 26 10 93 55Carrie Newsom, Study coordinator
[email protected]
Telephone :  04 26 73 28 35
Hepatology Department
103 Grande Rue de la Croix-Rousse
69004 Lyon
France
UniversitatKlinikum in Freiburg (Germany) Pr. Robert THIMME
[email protected]
Pr. Robert THIMME
[email protected]
Department of Internal Medicine
Clinic for Internal Medicine II – Gastroenterology,
Hepatology, Endocrinology and Infectiology
Hugstetter Street 55
79106 Freiburg
Germany
Hôpital Saint-Joseph (France) Pr. Marc BOURLIERE
[email protected]
Pr. Marc BOURLIERE
[email protected]
Hepato-gastroenterology department
26 boulevard de Louvain
13285 Marseille Cedex 8
France
Fondazione IRCCS Ca’ GrandaOspedale Maggiore Policlinico in Milan (Italy) Pr. Pietro LAMPERTICO
[email protected]
Pr. Pietro LAMPERTICO
[email protected]
Gastroenterology and Hepatology Division
Via Francesco Sforza 35
20122 Milan
Italy
University Hospital of Parma (Italy) Pr. Ovidio BUSSOLAFI
[email protected]
Prof. Gabriele Missale
[email protected]
Department of General and Specialized Medical AreaAziendaOspedalieraUniversitaria di Parma Via Gramsci 14
43126 Parma
Italy
Hôpital Pitié Salpêtrière (France) Pr. Dominique THABUT
[email protected]
Pr. Vlad RATZIU
[email protected]
Service towpath-gastroentérologie Hôpital Pitié Salpêtrière 47-83, boulevard de l’hôpital 75651 Paris cedex 13
France
CHU Hôtel-Dieu, Nantes (France) Dr Jérôme GOURNAY
[email protected]
Dr Jérôme GOURNAY
[email protected]
CHU Hôtel-Dieu Service d’hépato-gastro-entérologie
Institut des Maladies de l’Appareil Digestif 1 place Alexis Ricordeau 44093 Nantes Cedex 01
France
Vall d’Hebron University Hospital in Barcelona (Spain) Pr. Maria BUTI
[email protected]
Pr. Maria BUTI
[email protected]
Internal Medicine and Hepatology
Passeig de la Vall d’Hebron, 119
08035 Barcelona
Spain

Press contacts:

ELPA: [email protected]

ANRS | Emerging infectious Diseases: [email protected]